Related Experiment Video
Updated: Apr 6, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
[Chronic liver disease and thrombosis risk]
Insights
Chronic liver disease increases thrombosis risk, particularly portal vein thrombosis in cirrhosis. This review guides anticoagulation therapy tailored to bleeding risk and proposes treatment algorithms.
Area of Science:
- Hepatology
- Vascular Medicine
- Thrombosis Research
Context:
- Chronic liver disease (CLD) and cirrhosis are associated with complex coagulopathy.
- This coagulopathy paradoxically increases risks for both bleeding and thrombosis, especially in the portal vein and splanchnic circulation.
- Portal vein thrombosis (PVT) in cirrhosis portends a poor prognosis and is linked to decompensation events.
Purpose:
- To provide practical guidance on tailoring anticoagulation therapy for patients with cirrhosis and portal vein thrombosis.
- To review the current understanding of hypercoagulability in chronic liver disease.
- To propose an integrated treatment algorithm for cirrhotic PVT incorporating anticoagulation and transjugular intrahepatic portosystemic shunts (TIPS).
Summary:
- Anticoagulation therapy can achieve recanalization in recent PVT and prevent progression in chronic cases.
- Standard thrombosis prophylaxis is recommended for hospitalized cirrhotic patients.
- Individualized anticoagulation strategies should balance thrombosis risk against bleeding risk in cirrhosis.
Impact:
- This review aims to optimize management strategies for PVT in cirrhosis, potentially improving patient outcomes.
- It offers a framework for clinicians to make informed decisions regarding anticoagulation in this complex patient population.
- The proposed algorithm may enhance the efficacy of combined anticoagulation and TIPS for treating cirrhotic PVT.
Abstract:
The coagulopathy of chronic liver disease involves elevated risks for thrombosis in the portal vein and extra-splanchic sites. Hypercoagulability may moreover accelerate liver fibrosis progression. Cirrhosis-related portal vein thrombosis is associated with decompensation events and inferior prognosis; anticoagulation therapy achieves complete recanalization in -40% of recent thromboses and prevents thrombosis progression in chronic cases. Standard thrombosis prophylaxis seems appropriate for hospitalized cirrhotic patients. This review provides practical guidance to tailoring anticoagulation therapy in cirrhosis according to individual bleeding risk. We also propose an algorithm for using anticoagulation and transjugular intrahepatic portosystemic shunts in the treatment of cirrhotic portal vein thrombosis.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction

